Clinical Trials Logo

Multiple Myeloma, Refractory clinical trials

View clinical trials related to Multiple Myeloma, Refractory.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04688853 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients

Start date: May 13, 2021
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e. TEG002, in a dose escalation and expansion study in relapsed/refractory Multiple Myeloma patients. The study will comprise of a Dose Escalation Segment and an Expansion Segment. The study consists of a screening period, leukapheresis of mononuclear cells, and conditioning chemotherapy, followed by TEG002. All subjects continue to be followed regularly for safety and efficacy assessments until 1 year after TEG002 administration.

NCT ID: NCT04287855 Active, not recruiting - Clinical trials for Multiple Myeloma in Relapse

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Start date: August 28, 2020
Phase: Phase 2
Study type: Interventional

Study a quadruplet-based regimen with Minimal Residual Disease (MRD) 10-5 negative rate as primary end point in patients with early Relapsed or Refractory Multiple Myeloma. Therapeutic study, phase II, prospective, multicenter, open-label. The patients will be treated until progression. Each cycle of treatment lasts 28 days. Cycle 1 to 13 : treatment phase After cycle 13 : maintenance phase